Evaluation of effect of Curcumin on the serum levels of 12-inflammatory cytokines & highly sensitive C-reactive protein

Evaluation of effect of Curcumin on the serum levels of 12-inflammatory cytokines and highly sensitive C-reactive protein level in the patients with Non-alcoholic fatty liver disease (A double-blind, randomized, placebo-controlled trial)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015052322381N1

Enrollment

Registered

2016-09-17

Start date

2016-08-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD. nonalcoholic steatohepatitis

Interventions

Intervention 1: Curcumin Phytosome (Meriva) with dose 250 mg/day (phospholipidated curcumin, 250 mg equivalent to 50 mg curcumin). Intervention 2: Curcumin C3 complexTM (500 mg) plus BioperineTM (5 mg

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18–65 years The diagnosis of fatty liver using ultrasound

Exclusion criteria

Exclusion criteria: Women with pregnancy/lactation Alcoholic liver disease Taking anti-inflammatory drugs such as Curtin Acute or chronic liver disorders such as viral (hepatitis B and C) and autoimmune hepatitis Metabolic liver disorders including hemochromatosis and Wilson’s disease, Budd–Chiari syndrome Having other medical disorders such as cardiovascular diseases and cancer Taking liver enzyme enhancement drugs Have severe heart and lung disease Hypothyroidism and hyperthyroidism Alpha-1 antitrypsin deficiency Celiac disease

Design outcomes

Primary

Measure	Time frame
NAFLD grade. Timepoint: Before intervention and two months after intervention. Method of measurement: Sonography.;Tumor necrosis factor alpha (TNF-a). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;High-sensitivity C-reactive Protein (hs-CRP). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto-analyzer BT-2000.;Interleukin 6 (IL-6). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Interleukin 10 (IL-10). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Monocyte Chemoattractant Protein-1 (MCP-1). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.	—

Measure

Time frame

NAFLD grade. Timepoint: Before intervention and two months after intervention. Method of measurement: Sonography.;Tumor necrosis factor alpha (TNF-a). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;High-sensitivity C-reactive Protein (hs-CRP). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto-analyzer BT-2000.;Interleukin 6 (IL-6). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Interleukin 10 (IL-10). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Monocyte Chemoattractant Protein-1 (MCP-1). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.

—

Secondary

Measure	Time frame
Aspartate Aminotransferase (AST). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Alanine Aminotransferase (ALT). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Alkaline Phosphatase (ALP). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Fasting blood sugar (FBS). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Triglyceride (TG). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Total cholesterol (TC). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;High-density lipoprotein cholesterol (HDL-C). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Low-density lipoprotein cholesterol (HDL-C). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.	—

Measure

Time frame

Aspartate Aminotransferase (AST). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Alanine Aminotransferase (ALT). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Alkaline Phosphatase (ALP). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Fasting blood sugar (FBS). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Triglyceride (TG). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Total cholesterol (TC). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;High-density lipoprotein cholesterol (HDL-C). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.;Low-density lipoprotein cholesterol (HDL-C). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto Analyzer BT-2000.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Seyed Reza Mirhafez

Neyshabour University of Medical Sciences

mirhafezr@gmail.com+98 51 4334 4011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026